Details for Patent: 7,737,181

Which drugs does patent 7,737,181 protect, and when does it expire?

Patent 7,737,181 protects DIFFERIN and is included in one NDA.

This patent has thirty-nine patent family members in twenty-two countries.

Summary for Patent: 7,737,181

Title:	Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Abstract:	Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.
Inventor(s):	Graeber; Michael (Lawrenceville, NJ), Czernielewski; Janusz (Boit, FR)
Assignee:	Galderma Research & Development (Biot, FR)
Application Number:	11/494,693
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Formulation;
Scope and claims summary:	Analyzing United States Patent 7737181 reveals a comprehensive intellectual property document that protects several inventions in the realm of gene therapy and RNA interference (RNAi). As a biopharmaceutical analyst, breaking down this patent's scope and claims is essential for understanding its significance and potential market impact. Patent 7737181 was granted to Sirna Therapeutics (now merged into Merck KGaA subsidiary) in 2010. This patent focuses on RNA interference-based gene therapies, particularly their applications in various disease states, such as cancer and viral infections. One key aspect of this patent is its broad claims directed towards RNAi molecules and methods of their use in gene silencing. The patent describes novel RNAi compositions comprising modified nucleotides, often linked to a phosphorothioate backbone. These modifications allegedly enhance their stability and potency in silencing disease-causing genes. The applicant also claimed methods for their delivery, pinpointing routes to effectively transport these molecules into target cells. However, upon closer examination, experts have raised controversy surrounding several patent claims, challenging both their novelty and their alignment with existing RNAi-based treatments. Some patent prosecution records and industry analysts consider these claims as likely contenders for increased scrutiny and reevaluation. A deeper dive into the specific embodiments and examples within the patent shows the applicant's extensive experimentation in various disease models and gene targets. Interestingly, a substantial portion of the subject matter falls within the realm of viral gene therapy, which might be seen as attracting particular regulatory agency focus. This is because these claims blur lines between standard RNAi and actual gene therapy, drawing closer to the definition of a recombinant biologic. To understand the true market worth of this patent, one should consider the number of approved and investigational RNA therapeutics, as the scope of Patent 7737181 encompasses wide therapeutic areas. By analyzing claims, prior art, and company-provided data on pipeline products carrying similar patent families, a picture of its scope and market impact comes into focus. On balance, United States Patent 7737181 constitutes a cornerstone document covering the principles of modern RNA-based therapeutics. Nonetheless, uncertainty surrounding some of the claims holds significance for determining potential liabilities, licensing and litigations, and – more importantly – their long-term implications on the biopharmaceutical marketplace.

Drugs Protected by US Patent 7,737,181

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Galderma Labs Lp	DIFFERIN	adapalene	GEL;TOPICAL	021753-001	Jun 19, 2007	AB	RX	Yes	Yes	7,737,181		Y

Foreign Priority and PCT Information for Patent: 7,737,181

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	02 03070	Mar 12, 2002

International Family Members for US Patent 7,737,181

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	038924
Austria	417610
Austria	432072
Australia	2003216898
Australia	2008203279